Meiragtx Holdings plc MGTX 深 滬
等待開盤 12-17 09:30:00 美东时间
8.46
-0.440
-4.94%
華盛通- 最 高9.15
- 今 開8.84
- 成交量 22.99万股
- 最 低 8.31
- 昨 收 8.90
- 總市值 6.81亿
- 52周最高 9.73
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 4.55
- 委 比 54.65%
- 總股本 8044.75万
- 歷史最高 30.23
- 量 比 0.86
- 振 幅 9.44%
- 歷史最低 3.49
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
HC Wainwright & Co. Initiates Coverage On MeiraGTx Hldgs with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy rating and announces Price Target of $20.
11-24 23:14
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
MeiraGTx Hldgs Q3 EPS $(0.62) Misses $(0.50) Estimate, Sales $410.000K Miss $6.960M Estimate
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 23.51 percent. This is a 12.73 percent decrease over losses of $(0.55) per share from
11-13 21:11
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
11-11 21:07
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.
11-10 22:11
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Raymond James Initiates Coverage On MeiraGTx Hldgs with Strong Buy Rating, Announces Price Target of $29
Raymond James analyst Christopher Raymond initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Strong Buy rating and announces Price Target of $29.
10-22 01:40
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
MeiraGTx presents two posters at ESGCT 2025 Annual Congress. Poster P0089 highlights novel AAV capsids developed for efficient intravitreal delivery, showing improved transduction efficiency in retinal cells and potential for treating ocular diseases. Poster P0170 discusses scaling up a perfusion-based AAV manufacturing process to 40L bioreactors, enhancing yield and reducing costs. The company emphasizes its advanced manufacturing capabilities a...
10-07 12:00
